Inflammasomes are important mediators of prostatic inflammation associated with BPH
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-9255
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Inflammasomes are important mediators of prostatic inflammation associated with BPH ; volume:12 ; number:1 ; day:17 ; month:5 ; year:2015 ; pages:1-8 ; date:12.2015
Journal of Inflammation ; 12, Heft 1 (17.5.2015), 1-8, 12.2015
- Urheber
-
Kashyap, Mahendra
Pore, Subrata
Wang, Zhou
Gingrich, Jeffrey
Yoshimura, Naoki
Tyagi, Pradeep
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12950-015-0082-3
- URN
-
urn:nbn:de:101:1-2021082823032865493465
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kashyap, Mahendra
- Pore, Subrata
- Wang, Zhou
- Gingrich, Jeffrey
- Yoshimura, Naoki
- Tyagi, Pradeep
- SpringerLink (Online service)
Ähnliche Objekte (12)
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Lipid mediators in eye inflammation
Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization
Mediators of liver inflammation and carcinogenesis
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway
Cytotoxic mediators of inflammation and host defence
Medikamentöse BPH-Behandlung
B-P-H
Blickpunkt Benigne Prostatahyperplasie (BPH)
Therapie der BPH-Erkrankung
Longitudinal association between the dynamic nature of depression with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Lipid mediators in eye inflammation
Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization
Mediators of liver inflammation and carcinogenesis
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway
Cytotoxic mediators of inflammation and host defence
Medikamentöse BPH-Behandlung
B-P-H
Blickpunkt Benigne Prostatahyperplasie (BPH)
Therapie der BPH-Erkrankung
Longitudinal association between the dynamic nature of depression with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Lipid mediators in eye inflammation
Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization
Mediators of liver inflammation and carcinogenesis
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway
Cytotoxic mediators of inflammation and host defence
Medikamentöse BPH-Behandlung
B-P-H
Blickpunkt Benigne Prostatahyperplasie (BPH)
Therapie der BPH-Erkrankung